Ohio State Research Foundation — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$200,192	22
2024	Research	$202,542	18
2023	Research	$44,445	7
2022	Research	$353,733	13
2021	Research	$390,167	14
2020	Research	$151,402	14
2019	Research	$260,406	20

Breakdown

Who paid Research payments · program years 2019–2025

Novocure Inc. $357,965 13 payments
Merck Sharp & Dohme Corporation $348,681 7 payments
Clovis Oncology, Inc. $332,006 33 payments
AbbVie, Inc. $184,127 14 payments
Genentech, Inc. $117,973 10 payments
Genmab U.S., Inc. $103,579 15 payments
TESARO, Inc. $99,121 4 payments
pharmaand GmbH $59,435 12 payments

Studies the money was for Research payments · program years 2019–2025

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) $391,441 45 payments
EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer $357,965 13 payments
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $222,795 4 payments
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) $114,040 9 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Hrd-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy $99,121 4 payments
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047 $93,511 1 payment
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer $93,311 4 payments
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) $70,087 5 payments
Multicenter multi cohort open label Ph2 study of biomarker driven therapies for recurrent R OC pat $67,086 8 payments
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors $45,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.